Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

The first-quarter 2023 biopharma earnings season saw a clutch of leading drug developers cull pipeline programs, with Biogen, Novartis, and Sanofi among the companies to discard clinical-phase candidates in recent updates. The companies are looking to restructure research and development, cut costs, and shift from high-risk drug development to focus areas.